-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

JPMorgan Adjusts Pliant Therapeutics Price Target to $47 From $51, Maintains Overweight Rating

JPMorgan Adjusts Pliant Therapeutics Price Target to $47 From $51, Maintains Overweight Rating

MT Newswires · 03/10/2023 04:04